RxDoctor Payments Data

Katrina Stachowiak, PA

Physician Assistant · Lexington, MINPI 1801862842

Payments from drug & device makers

$1,771in general payments, 2019–2025

Across 65 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$527
  • AbbVie$443
  • Novo Nordisk$227
  • Exact Sciences$122
  • QOL Medical, LLC$108
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108
  • plus $235 from 6 others

What the payments were for

  • Food & beverage$1,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,771 in reported general payments places this provider in the 80th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$49,883
Medicare patients
135
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$26,567
FarxigaDapagliflozin Propanediol21$18,795
RybelsusSemaglutide19$17,424
JanuviaSitagliptin Phosphate28$16,500
OzempicSemaglutide15$14,815
MyrbetriqMirabegron30$13,923
XareltoRivaroxaban12$11,810
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,053
EntrestoSacubitril/Valsartan12$7,923
JanumetSitagliptin Phos/Metformin Hcl11$6,247
Albuterol Sulfate HfaAlbuterol Sulfate80$2,763
Celecoxib26$2,297
Atorvastatin Calcium126$1,676
Losartan Potassium115$1,483
Levothyroxine Sodium111$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$227$32,23934 claims
AstraZenecaFarxiga$527$18,79521 claims
GSKTrelegy Ellipta$22$10,05314 claims
Sanofi-aventis U.S. LLCLantus$20$1,13519 claims
AbbVieSynthroid$443$1,02321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Lexington

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →